Bayer's patent for blood thinner Xarelto invalid, UK court rules

Bayer's (BAYGn.DE) patent covering its best-selling blood thinner Xarelto is invalid, London's High Court ruled on Friday in a blow to the German drugmaker.
The company's blockbuster Xarelto drug generated nearly $4.1 billion in revenue in 2023, according to research firm Statista.